ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 893

Identification of Axial Spondyloarthritis Patients in a Large Dataset: The Development and Validation of Novel Methods

Rebecca S. Overbury1, Shaobo Pei2, Gopi Penmetsa2, Grant W. Cannon2, Daniel O. Clegg3, Brian Sauer4 and Jessica Walsh5, 1Internal Medicine, Divison of Rheumatology, University of Utah Medical Center, Salt Lake City, UT, 2University of Utah, Salt Lake City, UT, 3Division of Rheumatology, University of Utah Medical Center, Salt Lake City, UT, 4Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, 5Rheumatology, Salt Lake City Veterans Affairs, Salt Lake City, UT

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: axial spondyloarthritis, big data and diagnosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: 3S088 ACR Abstract: Spondyloarthritis Incl PsA–Clinical I: Axial SpA Epidemiology (892–897)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Big data research in axial spondyloarthritis (axSpA) is limited by a lack of adequate methods for identifying axSpA patients, since there are no billing codes for most subtypes of axSpA. The objective of this study was to develop accurate axSpA identification methods to enable previously impractical observational research in axSpA.

Methods: The population included 600 Veterans with risk factors for axSpA in the Veteran Health Administration (January 1, 2005 through June 30, 2015). Clinical experts reviewed medical records to determine axSpA status. axSpA identification algorithms were developed in a subset of 451 patients (training set) and tested in the remaining 149 patients (testing set).  Forty-nine variables anticipated by clinical experts to be predictive of an axSpA diagnosis were selected for algorithm development. The variables included demographics, billing codes, provider utilization patterns, medication dispensations, laboratory results, and affirmative language for key disease features (spondyloarthritis, sacroiliitis, and HLA-B27 positivity) that was extracted from the free text of documents with natural language processing (NLP). Three algorithms were developed: the Spond NLP Algorithm (NLP algorithm as a single variable), High Feasibility Algorithm (16 coded variables), and Full Algorithm (all coded and NLP variables).  Random Forest, 5-fold cross validation, and Random Forest Gini Scores were used for algorithm development, testing, and variable prioritization.

Results: In the testing set, the sensitivity of the Spond NLP Algorithm was 95.0% and the specificity was 78.0%.  For the High Feasibility Algorithm, the sensitivity was 85.0% and the specificity was 93.6%. For the Full Algorithm, the sensitivity was 87.5%, and the specificity was 91.7% (Figure 1). The areas under the curve with the receiver operating characteristic analysis for the testing set were 0.86 for the Spond NLP Algorithm, 0.94 for the High Feasibility Algorithm, and 0.96 for the Full Algorithm (Figure 2).

Conclusion: Sensitive and specific algorithms were developed for identifying axSpA patients for big data research. These algorithms offer a range of performance and feasibility attributes that may be appropriate for a broad array of axSpA research. 

Figure 1. Sensitivity, specificity, PPV, and NPV of axSpA identification algorithms (n=149)

PPV = positive predictive value, NPV = negative predictive value                                                               Figure 2. Receiver operating characteristic curves (testing set, n=149)          


Disclosure: R. S. Overbury, None; S. Pei, None; G. Penmetsa, None; G. W. Cannon, None; D. O. Clegg, None; B. Sauer, None; J. Walsh, None.

To cite this abstract in AMA style:

Overbury RS, Pei S, Penmetsa G, Cannon GW, Clegg DO, Sauer B, Walsh J. Identification of Axial Spondyloarthritis Patients in a Large Dataset: The Development and Validation of Novel Methods [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/identification-of-axial-spondyloarthritis-patients-in-a-large-dataset-the-development-and-validation-of-novel-methods/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-axial-spondyloarthritis-patients-in-a-large-dataset-the-development-and-validation-of-novel-methods/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology